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Abstract  
The spectrum of systemic autoinflammatory disorders broadens continually. In part, this is due to 
the more widespread application of massive parallel sequencing, helping with novel gene discovery 
in this and other areas of rare diseases. Some of the conditions that have been described fit neatly 
into a conventional idea of autoinflammation. Others, such as Interferon-mediated 
autoinflammatory diseases, are broadening the concept which we consider to be autoinflammatory 
disorders. There is also a widening of the clinical phenotypes associated with certain genetic 
mutations, as genetic testing is used more regularly and increasing numbers of patients are 
screened.   It is also increasingly evident that both autoinflammatory and autoimmune problems are 
frequently seen as complications of primary immunodeficiency disorders.  
The aim of this review is to provide an update on some recently discovered conditions, and to 
discuss how these disorders help to define the concept of autoinflammation. The review will also 
cover recent discoveries in the biology of innate-immune mediated inflammation, and describe how 
this has provided the biological rationale for using anti-IL-1 therapies in the treatment of many such 
conditions. Finally, we discuss the importance of recognising somatic mutations as causes of 
autoinflammatory clinical phenotypes, and provide practical advice on how this could be tackled in 
everyday clinical practice.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The field of autoinflammatory disorders has expanded significantly in the last decade. In 
addition to the prototypic conditions such as hereditary fever syndromes, which have defined this 
field, there are number of new conditions which are included in this spectrum. Furthermore, recent 
advances in basic sciences have provided new insights into biology of the innate-immune mediated 
inflammatory responses. The aim of this review is to highlight some of the recently described 
disorders which have helped to expand the concept of autoinflammation. In addition, we will discuss 
new findings related to the function of pyrin that provide important insights into the biology of 
inflammatory responses. Finally, we will discuss new approaches toward investigating patients who 
present with autoinflammatory-like disorders.  
 
Expanding concept of autoinflammation  
IL-1 mediated autoinflammatory syndromes 
Familial Mediterranean Fever (FMF) is the first systemic autoinflammatory disorder (SAID) to 
be genetically defined. Biallelic mutations in the MEFV (MEditerranean FeVer) gene, encoding pyrin, 
were identified as a cause of FMF by two groups, working independently in 1997 1 2. However, it was 
not until 1999 that the concept of autoinflammation was first proposed 3. This followed the 
discovery of the genetic basis for another SAID, TNF receptor-associated periodic fever syndrome 
(TRAPS), where heterozygous mutations in the TNFRSF1 gene were shown to cause the disease 3.  
Both of these conditions are characterised by seemingly unprovoked episodic sterile inflammation 
manifesting as, but not limited to, unexplained pyrexias, skin rashes, serositis, arthralgia and 
myalgia. These episodes will usually resolve spontaneously and are not associated with production 
of autoantibodies or autoreactive T cells. In both conditions the cause relates to genetically 
determined dysfunction of the innate immune system. Pyrin is predominantly expressed in 
neutrophils, which are the main effector cells associated with inflammation in FMF, whilst the TNF 
signalling pathway is critical in early stages of the innate immune response. The term 
autoinflammation was therefore coined to capture these unique clinicopathological features of 
innate immune-mediated inflammation, which differentiate these disorders from disturbances in  
adaptive immune function, associated with established autoimmune disorders. The genetic basis of 
two other SAIDs, hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), due to biallelic 
mutations in the mevalonate kinase (MVK) 4 5, and cryopyrin-associated periodic fever syndromes 
(CAPS) due to heterozygous mutations in NLRP3 6 7, were identified shortly after the term 
autoinflammation was introduced. Both of these conditions are typical autoinflammatory disorders. 
In CAPS, gain of function mutations in NLRP3 result in inappropriate activation of the NLRP3 
inflammasome and dysregulated IL-1ɴ ƌĞůĞĂƐĞ 8, whilst in HIDS, the link between deficiency of 
mevalonate kinase activity and the pathological innate-immune inflammatory response was less well 
understood until very recently. However, it now appears that the biochemical and inflammatory 
pathways are closely linked, and that, in the case of HIDS, a defect of geranylgeranylation results in 
inappropriate IL- ?ɴƌĞůĞĂƐĞ9.  
Although from an immunopathogenic perspective these conditions initially seemed to 
comprise a heterogeneous group of disorders, they all share a common feature, which is 
responsiveness to IL-1 blockade. Both anakinra (recombinant anti-IL1 receptor antagonist) and 
canakinumab (anti-IL1ɴmonoclonal antibody) are now licensed for treatment of CAPS 10. The early 
reports from a phase III trial of canakinumab in TRAPS, HIDS and Colchicine Resistant (CR) FMF are 
very favourable for all three conditions 11. In addition, there are numerous case series reported in 
the literature describing successful use of anakinra and canakinumab for treatment of these 
disorders. Now that the basic biology of these conditions is much better understood, it is no surprise 
that IL-1 blockade is an effective treatment modality. However, even before this was fully realised, 
the favourable clinical response to IL-1 blockade became one of the defining features of 
autoinflammatory conditions. The IL-1 superfamily of cytokines comprises of 11 members, and, in 
addition to IL-1ɴ ? there are other members of this family, which have been implicated in the 
pathogenesis of SAIDs. Deficiency of naturally IL-1 Receptor antagonist (Ra) or DIRA was described in 
2009 12 and deficiency of IL-36Ra or DITRA, as a cause of generalised pustular psoriasis with systemic 
inflammation, was identified in 2011 13.  
IL-18 mediated autoinflammation and susceptibility to MAS 
Despite the fact that the NLRP3 inflammasome processes both pro-IL- ?ɴĂŶĚƉƌŽ-IL-18 (another 
potent proinflammatory cytokine from the IL-1 superfamily) into their active forms, targeted IL- ?ɴ
blockade alone remains extremely effective in patients with CAPS. However, recently a new 
autoinflammatory disorder was identified, which is characterised by excessive IL-18 release, due to 
gain-of-function mutations in NLRC4. Two mutations, p.V337S and p.V341A, located in the NACHT 
domain, arising de novo in two unrelated families, were shown to cause an autoinflammatory 
phenotype associated with enterocolitis and macrophage activation syndrome (MAS) 14 15. In total, 
four patients were described, three from one family and one other sporadic case. All patients 
presented with recurrent fevers and early onset enterocolitis; one of these patients died in infancy 
and three out of four developed MAS, two in infancy and one later in life. NLRC4 is an innate 
immune sensor and, similarly to NLRP3, when activated it associates with ASC (apoptosis associated 
speck-like protein containing a CARD) and leads to the assembly of a caspase-1 activating 
inflammasome. However, mutated forms of the NLRC4 inflammasome, which in transfection 
experiments were shown to have increased tendency towards oligomerisation and, therefore, 
activation, appear to process IL-18 in preference over IL-1ɴ. Although the serum levels of both 
cytokines were elevated in all patients, the IL-18 levels were several folds higher then IL-1ɴ, unlike 
the findings in patients with Chronic Infantile Neurologic, Cutaneous, Articular syndrome (CINCA) 
also known as neonatal onset multisystem inflammatory disease (NOMID). Additional studies also 
showed increased spontaneous and induced macrophage activation and pyroptosis as the main 
source of elevated IL-18. These cases illustrate that an intrinsic monocyte defect associated with 
excessive IL-18 release can result in MAS.  This pathogenic mechanism may be important in clinical 
scenarios, where a cytotoxic defect is not thought to be causative  of MAS, and, therefore, IL-18 
could be a potential therapeutic target in conditions such as systemic juvenile idiopathic arthritis 
(sJIA). Interestingly, another activating NLRC4 mutation p.H443P has been identified as a cause of 
familial cold autoinflammatory syndrome (FCAS) in a large Japanese family 16.  None of these 
patients developed MAS, despite the fact that this mutation was also located in the NACHT domain; 
however, it is unknown if their IL-18 levels were significantly elevated, since this was not measured. 
As more patients with NLRC4 mutations are identified in the future it is possible that we will see a 
spectrum of clinical phenotypes associated with this gene, which is reminiscent of the history of 
CAPS.   
 
A20 haploinsufficiency  
Another novel immunopathogenic mechanism that leads to the development of SAID has 
recently been identified by Zhou et al17. TŚĞĂƵƚŚŽƌƐĚĞƐĐƌŝďĞĞŚĕĞƚ ?Ɛ disease-like disorder due to 
high penetrance heterozygous mutations in TNFAIP3 (tumor necrosis factor ?induced protein 3; also 
known as A20). This protein has an N terminal ovarian tumour (OTU) domain, which is responsible 
for the deubiquinating activity of this protein, and seven zinc-finger (ZnF) domains, which have an E3 
ubiquitin ligase function. Consequently, A20 regulates the ubiquitination status and, therefore, also 
regulates the levels and function of a number of intracellular proteins that are targeted for 
proteasome-mediated degradation. The majority of disease-causing mutations (5/6) were found in 
ƚŚĞKdhĚŽŵĂŝŶ ? ůĞĂĚŝŶŐ ƚŽĂ ƚƌƵŶĐĂƚĞĚƉƌŽƚĞŝŶǁŚŝĐŚǁĂƐŶŽƚĞǆƉƌĞƐƐĞĚ ŝŶƉĂƚŝĞŶƚƐ ?WD ?dŚŝƐ
appears to result in a haploinsufficient state of wild type A20, that is associated with increased 
activation of NF-ʃB and the mitogen-activated protein (MAP) kinases, p38 and JNK, due to increased 
ĚĞŐƌĂĚĂƚŝŽŶ ŽĨ /ʃɲ ? ĂŶ E&-ʃ inhibitor. IʃBɲ is normally deubiqunitated by A20, preventing its 
destruction by the ƉƌŽƚĞĂƐŽŵĞ ? /ʃɲ ŝŶ ƚƵƌŶ ƉƌĞǀĞŶƚƐ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ŽĨ /<ɲ ?/<<ɴ ? ǁŚŝĐŚ ŝƐ
necessary for activation of NF-ʃB and nuclear translocation of the p65 component of the NF-ʃB 
complex.  Altogether this leads to a strong pro-inflammatory state, which was illustrated by 
significantly increased levels of pro-inflammatory cytokines (IL-1ɴ, TNF, IL-6, IL-18, IL- ? ? ?ŝŶƉĂƚŝĞŶƚƐ ?
sera and also in supernatant from patient-derived PBMCs stimulated with LPS. Another potential 
effect of A20 haploinsufficiency was suggested by a murine study 18 19 that demonstrated a negative 
ĞĨĨĞĐƚŽĨƚŚŝƐƉƌŽƚĞŝŶŽŶE>ZW ? ŝŶĨůĂŵŵĂƐŽŵĞĂĐƚŝǀĂƚŝŽŶĂŶĚƚŚŝƐǁĂƐ ŝŶĚĞƉĞŶĚĞŶƚŽĨ ? ? ?ƐĞĨĨĞĐƚ
on NF-ʃB regulation. Interestingly, constitutive activation of the NLRP3 inflammasome was also 
demonstrated in patient-derived PBMCs and the fact that anti-IL1 inhibition was used successfully in 
one patient, albeit at a very high dose, supports the notion that NLRP3 inflammasome dysregulation 
is one of the consequences of A20 haploinsufficiency.   
 
Interferon-mediated autoinflammatory diseases 
Although dysregulation of IL-1 release is still one of the main biological outcomes resulting 
from the genetic mutations associated with SAID, there is now a wide range of conditions, with an 
autoinflammatory clinical phenotype, but due to chronic excessive type I interferon (IFN) 
production. The term, type I interferonopathy, was proposed in 2011 20, to describe this growing 
number of monogenic disorders, and, more recently, an umbrella term interferon-mediated 
autoinflammatory diseases (IMAD) was introduced.  It is beyond the scope of this review to provide 
a detailed account of these conditions, and this topic was recently comprehensively covered 21, but it 
is worthwhile briefly mentioning some of the main biological and clinical aspects of these conditions 
that separate them from IL-1 mediated disorders. In Aicardi-Goutières syndromes (AGS) a range of 
genetic mutations lead to excessive IFN-producing responses, due to several different mechanisms. 
These include accumulation of endogenous nucleic acids, enhanced sensitivity or spontaneous 
activation of nucleic acids sensors, such as RIG-I or MDA5, dysregulated negative feedback 
regulation of nucleic acid-sensing pathways and, lastly, defects in pathways that modulate type I IFN 
responses, which are not due to nucleic acid sensing 21. Another group of disorders that come under 
this category includes systemic inflammation, panniculitis, and myositis due to proteasome-
associated autoinflammatory syndrome (PRAAS) or chronic atypical neutrophilic dermatosis with 
lipodystrophy and elevated temperature (CANDLE). Initially, all affected individuals with 
PRAAS/CANDLE were found to have biallellic mutations in PSMB8, resulting in deficiency 
of proteasome ƐƵďƵŶŝƚɴ  ? (PSMB8), leading to abnormal function of the immunoproteosome 22-24. 
However, more recently a similar phenotype was also described in patients with loss of other 
proteasome subunits, respectively due to the mutations in PSMA3, PSMB4 and PSMB9 genes 25.  
Patients with PRAAS present with a constellation of signs and symptoms that include recurrent 
fevers, joint contractions with muscle atrophy, partial lipodystrophy, hepatomegaly and basal 
ganglia calcification. Although IFNs are known to induce formation of immunoproteosome, it is still 
not entirely clear how immunoproteosome dysregulation leads to elevated IFNs, increased IFN 
signature, high serum IL-6 levels and constitutive STAT 1 phosphorylation, which have all been 
described in these patients. Many patients also produce non-specific autoantibodies, which are not 
linked with an obvious autoimmune process. Patients with AGS tend to present with a less obvious 
inflammatory phenotype. Often this disorder mimics in utero acquired viral infection, and patients 
classically present with leukoencephalopathy, typified by basal ganglia calcifications and progressive 
cerebral atrophy, as well as lymphocytosis and elevated IFN-ɲŝŶĐĞƌĞďƌŽƐƉŝŶĂůĨůƵŝĚ ?^ŽŵĞĐůŝŶŝĐĂů
features of AGS tend to resemble SLE, including arthritis, thormobocytopenia, lymphopenia and 
antinuclear antibodies. SLE is considered to be a prototypic autoimmune disorder, in which the 
pathogenesis and breakdown of adaptive-immune control is linked with high IFN drive, but there are 
also studies which show direct effects on the innate immune cells in SLE 26. It seems that high IFN 
drive can lead to either a clinical phenotype that is either predominantly autoinflammatory in 
character, or results in the breakdown of self-tolerance, which is a cardinal feature of classical 
autoimmune diseases. The immunological disease continuum (IDC) was proposed in 2006 27, as a 
way of classifying the majority of inflammatory disorders according to their autoimmune or 
autoinflammatory characteristics, with monogenic autoimmune and monogenic autoinflammatory 
diseases located at opposite ends of the IDC spectrum.   
It would certainly seem that IMADs could be classified in this fashion. In many chronic 
inflammatory disorders there is a significant overlap of autoinflammatory and autoimmune features, 
with rheumatoid arthritis 28being one such example . It is probably an oversimplification, to an 
extent, to consider abnormalities of either the innate of adaptive immune systems in isolation, since, 
as demonstrated, by the IMADs, over time abnormalities within innate immune system will 
eventually trigger pathogenic responses in the adaptive immune system. This phenomenon has 
recently also been recognised to occur in IL-1 mediated autoinflammatory disorders. It has been 
known for some time that patients with CAPS have higher levels of TH-17 cells, which are typically 
linked with autoimmunity, but in these patients the presence of TH-17 cells has not resulted in 
clinically obvious autoimmune disease 29. Nevertheless, it is thought that these cells might be 
responsible for the more chronic inflammatory response. A recent paper by Arbore et al, has 
demonstrated that NLRP3 inflammasome activity within CD4 T cells is necessary to drive TH-1 
differentiation and for production of optimal IFN-ɶƌĞƐƉŽŶƐĞƐĚƵƌŝŶŐĂǀŝƌĂů ŝŶĨĞĐƚŝŽŶƐ 30. They also 
showed that CAPS patients had hyperactive Th1 responses and that this was associated with 
increased IL-1ɴ and IFN-ɶƉƌŽĚƵĐƚŝŽŶďǇdŚ ? ?dĐĞůůƐ ?dŚĞƌĞĨŽƌĞ ŝƚƐĞĞŵƐƚŚĂƚŽǀĞƌůĂƉďĞƚǁĞĞŶ
the innate and adaptive immune responses is probably even greater than previously thought. With 
this in mind, a classification model such as IDC can still provide a useful template to classify chronic 
inflammatory diseases.  
 
Immunodeficiency and immune dysregulation overlap 
It has been recognised, for some time now, that immune-dysregulation is a frequent feature 
of many primary immunodeficiencies (PIDs). In the case of the newly described CTLA4 
haploinsuficiency, in addition to the common variable immunodeficiency (CVID)-like phenotype, 
these patients also develop classical autoimmune complications, such as autoimmune cytopenias, 
and end organ damage, due to extensive autoreactive CD4+ T cell infiltrates 31. On the other hand, 
another group of patients with immunodeficiency of CVID-like characteristics, due to gain-of ?
function mutations in ƉŚŽƐƉŚŽůŝƉĂƐĞɶ ? (PLCy2), were found to suffer from cold-induced urticaria 
32, which is also a features of FCAS, a prototypic autoinflammatory disorder. In this condition, known 
as cold-induced urticaria, atopy, and immune dysregulation due to alterations in PLCɶ2 or PLAID, the 
mutated PLCɶ2 leads to increased calcium flux, particularly at low temperatures. This appears to 
have a different effect on the activity of various immune cells, leading to reduced B cell function, but 
increased degranulation of mast and other cells of the innate immune system at cold temperatures. 
This overlap between immunodeficiency and immune dysregulation is also found in some fairly well- 
established disorders. Deficiency of recombinase-activating genes 1 and 2 (RAG1/2) is typically 
associated with various degrees of immunodeficiency, including severe combined immunodeficiency 
(SCID), and, more recently, some hypomorphic mutations have been associated with CVID-like 
phenotype 33. However, RAG1/2 function is also necessary for elimination of autoreactive T and B 
cells as well as development of both central and peripheral tolerance 34.  Therefore, it is not entirely 
surprising that patients with RAG deficiency are found to have a broad spectrum of antibodies 
against self-antigens, including cytokines 35.  In the case of chronic granulomatous disease (CGD), 
mutations in in any one of the five components of the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase complex in phagocytes lead to a defective oxidative burst and susceptibility to 
invasive bacterial and fungal infections. However, many of these patients also develop severe 
inflammatory complications, including colitis. It has been demonstrated that macrophages from 
these patients also have impaired autophagy and, as a result of this, show increased IL-1ɴ release 36. 
Treatment of these patients with anakinra has resulted in rapid and sustained improvements in 
colitis.  
We therefore propose to extend the IDC to include various PIDs that have either 
autoinflammatory or autoimmune manifestations (Figure 1). Although the list of conditions we 
propose to include is not exhaustive it provides a starting point towards more comprehensive 
classification of immune-mediated disorders.  
 
Widening spectrum of pyrin-associated autoinflammatory diseases 
Although FMF was the first SAID to be genetically defined it is only recently that the biological 
function of pyrin is being fully elucidated. It was the perceived autosomal recessive mode of 
inheritance for FMF that initially led to the impression that the mutations seen within MEFV were 
likely to result in loss of function, thus making pyrin a negative modulator of inflammation. However 
almost all 125 variants within MEFV, known to be causative, are of a missense nature, whereas null 
mutations are extremely rare 37. Furthermore, about 30% of patients with clinical phenotype of FMF 
have only single mutated allele in MEFV, and there are also reports of seemingly autosomal 
dominant mode of inheritance in some families 38 39. Animal studies have shown that the FMF 
phenotype can only be achieved in knock-in-mice harbouring FMF-associated mutations of the gene 
encoding human pyrin, whilst MEFV knock-out, or pyrin deficient mice do not have any obvious 
clinical phenotype.  All these observations suggest that the mutated pyrin has a pro-inflammatory or 
gain-of  ?function effect, but that the emergence of the full clinical phenotype is dependent on the 
gene dosage of the mutated proteins. These earlier murine studies have also shown that mutant 
pyrin causes increased release of IL- ?ɴ ĂŶĚ ƚŚĂƚ ƚŚŝƐ ǁĂƐ ŶŽƚ ĚĞƉĞŶĚĞŶƚ ŽŶ E>ZW ? ďƵƚ ŽŶ ^ ?
suggesting the existence of separate pyrin inflammasome complex.   
          More recently Xu et al. have demonstrated that bacterial modifications, induced by toxins, 
such as Clostridium difficile toxin B (TcdB), in the switch I region of Rho GTPases (e.g. deamidation, 
ŐůǇĐŽƐǇůĂƚŝŽŶ ?ǁĞƌĞ ŝŶƐŽŵĞǁĂǇ   ‘ƐĞŶƐĞĚ ?ďǇƚŚĞƉǇƌŝŶ ŝŶĨůĂŵŵĂƐome, resulting in IL- ?ɴĂŶĚ />-18 
release 40. Although they did not map out the entire pathway the authors did show that pyrin 
activation was depended on interaction with 14-3-3 protein; it had been shown previously that this 
interaction was dependent on the phosphorylation of S242 and S208 pyrin residues41.  
Desphosphorylation of these two residues, which occurs upon exposure to TcdB, leads to release of 
the inhibitory 14-3-3 protein and activation of pyrin inflammsome, which further is dependent on 
ASC and caspase-1.  
The mapping of this pathway was carried out further by Park et al. who showed that inactivation 
of RhoA by bacterial toxin-mediated modifications leads to inactivation of RhoA effector kinases 
PKN1 and PKN2, which, in turn, maintain the phosphorylation status of S242 and S208 pyrin residues 
9. This process was recapitulated by demonstrating the range of effects certain MEFV mutations 
have on this pathway. For example, we have recently helped to describe a new autosomal dominant 
autoinflammatory disorder where patients present with a varied clinical phenotype, not suggestive 
of classical FMF but presenting with pyoderma gangrenosum, neutrophilic dermatosis, myalgia, 
fevers, arthralgia and persistently raised acute-phase reactants 42. All affected individuals were 
found to have heterozygous C-to-G substitution at c.726 in exon 2 of MEFV, which results in a serine-
to-arginine substitution at position 242 (S242R) in the pyrin protein. Effectively, this change resulted 
in constitutive activation of the pyrin inflammasome, since the loss of serine at position 242 
prevented phosphorylation of the protein and interaction with the inhibitory protein, 14-3-3. Park 
and colleagues also showed that mutations within the C-terminal B30.2 domain, where the majority 
of pathogenic FMF mutations are found, partially block the phosphorylation sites from access by 
kinases, such as PKN1. This could be due to conformational changes in the mutated proteins, but, 
nevertheless, the end result is to lower the threshold for activation of the pyrin inflammasome. They 
also showed that the defective geranylgeranylation, which occurs in HIDS, also leads to inactivation 
of the RhoA effector kinases, PKN1 and PKN2, producing similar effects on the pyrin inflammasome, 
as seen in FMF.  
Vasculopathy as manifestation of autoinflammatory process 
      Work by two independent groups in 2014 led to the identification of autosomal recessive 
mutations in the CECR1 gene 43 44; these mutations resulting in adenosine deaminase 2 (ADA2) 
protein deficiency, hence the abbreviation DADA2. Since these initial reports, over 40 cases have 
been documented. ADA is an enzyme integral to maintenance of adenosine concentrations in the 
cell, the latter of which has a regulatory role in the activation or silencing of several intracellular 
pathways 45. Although the pathology is well understood with regards to ADA1 deficiency resulting in 
severe combined immunodeficiency, ADA2 associated pathogenesis remains unclear. Increasing 
evidence demonstrates the additional role of ADA2 as a growth factor to ascertain the monocytic 
lineage 45, with zebrafish models also portraying the role of ADA2 in normal endothelial 
development. Taken together with abnormal endothelial development and given the results of the 
work by Zhou et al. 43 showing that normal ADA2 promotes the differentiation of monocytes into 
anti-inflammatory macrophages, mutant ADA2 therefore promotes the onset of vasculitis. The 
findings of another 2014 report indicated that reduced ADA2 activity leading to substantial 
endothelial cell damage, was due to an underlying process driven by neutrophils  ? the latter 
hypothesised by the increased expression of neutrophilic derived genes 46, although this finding has 
yet to be seen in other cases.  
      These recessive, loss-of-function mutations in CECR1 are associated with vasculitis, fevers, stroke 
and dysregulation of the immune system. However, the phenotypic variance observed between 
patients with DADA2, such as localised to severe vasculitis, indicates both epigenetic and 
environmental factors may play a role in development of severe disease manifestations 47. This 
inherited type of early onset vasculitis bears resemblances to polyarteritis nodosa (PAN); a 
necrotising vasculopathy with its pathology also poorly understood.  
     Haemopoietic stem cell therapy (HSCT) presents as an efficacious choice of treatment, due to 
ADA2 expression primarily in bone marrow derived lineages.  As demonstrated in the reports of Van 
Montfrans et al. 47 and Van Eyck et al. 48 and successful treatment of patients harbouring the 
p.Arg169Gln CECR1 mutation further reiterates the origination of ADA2 largely from monocytes and 
macrophages. Other therapeutic options include anti-TNF therapy, anti-IL-6 therapy and fresh frozen 
ƉůĂƐŵĂĐŽŶƚĂŝŶŝŶŐ ? ?ƚŚŽƵŐŚƚŚĞůĂƚƚĞƌ ?ƐƉƌĂĐƚŝĐĂůity needs further assessment 49.  
      Broadening the spectrum of DADA2 associated conditions could perhaps present as an 
opportunity to unite an assortment of previously thought distinct syndromes. In addition to this, the 
possibility of identifying CECR1 mutations resulting in enzyme deficiency in other forms of vasculitis 
or indeed, different conditions associated with stroke and inflammation, could provide a deeper 
insight into the pathogenesis of such disorders. 
Systemic autoinflammatory disorders of unknown etiology and somatic mosaicism/mutations  
Despite the ongoing discovery of novel genetic causes for autoinflammatory disorders there 
is still a relatively large population of patients, estimated to be between 50-60%, who do not have a 
germline pathogenic mutation in any of genes associated with monogenic SAID 50. This is particularly 
relevant in adult clinical practice where sporadic cases of patients with features of SAID increasingly 
are recognised. Some of these cases were later discovered to carry low frequency somatic mutations 
in known SAID related genes, arising in the haematopoetic stem cells within the bone marrow51. The 
first inkling of this phenomenon as a cause of sporadic SAID arose from the observation that somatic 
mosaicism of NLRP3 ǁĂƐ ƚŚĞ ĐĂƵƐĞ ŽĨ ĚŝƐĞĂƐĞ ŝŶ ƉƌĞǀŝŽƵƐůǇ ŐĞŶĞƚŝĐĂůůǇ  ‘ŶĞŐĂƚŝǀĞ ? ĐĂƐĞƐ ŽĨ
EKD/ ?/E ? ^ŽŵĂƚŝĐŵŽƐĂŝĐŝƐŵ ?ǁŚŝĐŚ ŝƐĚĞĨŝŶĞĚĂƐƚŚĞ  ‘ŽĐĐƵƌƌĞŶĐĞŽĨƚǁŽŐĞŶĞƚŝĐĂůůǇĚŝƐƚŝŶĐƚ
ƉŽƉƵůĂƚŝŽŶƐ ŽĨ ĐĞůůƐ ? ǁŝƚŚŝŶ ĂŶ ŝŶĚŝǀŝĚƵĂů ? ŝƐ Ă ŵƵƚĂƚŝŽŶƚŚĂƚ ŽĐĐƵƌƐ postzygotically and can either 
affect a proportion or subtype of cells 52.  Somatic mosaicism in exon 3 of the NLRP3 gene was 
originally reported back in 2005, in a 15-year-old patient with CINCA, along with a negative family 
history for CAPS 53. Of the two variants discovered in this patient, the frequency of Y570C was found 
to be 16.7% in whole blood, indicating that a mutated NLRP3 gene in approximately a third of the 
cells were sufficient to trigger the disease; this particular Y570C variant was documented as being 
 ‘ƉŽƚĞŶƚ ŝŶ ŝŶĚƵĐŝŶŐ^ ĚĞƉĞŶĚĞŶƚE&-ŬĂĐƚŝǀĂƚŝŽŶ ? ?ƵŶůŝŬĞ ƚŚĞŽƚŚĞƌǀĂƌŝĂŶƚ  ?^ ? ? ?E ?Žƌ ƚŚĞǁŝůĚ
type (WT) gene alone. A case control study by Tanaka et al, indicated mosaicism as a major cause of 
CINCA (NLRP3 mosaicism present in 18 out of 26 patients; completely absent in healthy controls). 
Notably, no mutations were detected in the controls using conventional Sanger sequencing 
previously 54. More recently in 2015, Zhou et al. studied whole blood DNA from a previously 
identified NLRP3 mutation-negative patient (via Sanger sequencing) who had presented with fever, 
ĐŚŝůůƐ ĂŶĚ ŵǇĂůŐŝĂ ĨŽƌ ƐĞǀĞƌĂů ŚŽƵƌƐ Ăƚ Ă ƚŝŵĞ ? ǁŚĞŶ ďůŽŽĚ ǁĂƐ ƐƵďũĞĐƚĞĚ ƚŽ  ‘ƚĂƌŐĞƚĞĚ ĚĞĞƉ
ƐĞƋƵĞŶĐŝŶŐ ?ĂƉŽƚĞŶƚŝĂůŵƵƚĂƚŝŽŶǁŝƚŚŝŶƚŚĞNLRP3 gene was detected. Additional subcloning of the 
NLRP3 amplicons also validated the presence of a previously reported CAPS-related mutation 
 ‘Ɖ ?dǇƌ ? ? ?ǇƐ ? ?ǁŝƚŚ Ă ĨƌĞƋƵĞŶĐǇ ŽĨ ƚŚĞ ŵƵƚĂŶƚ ĂůůĞůĞ  ?' ? ĂƚĂƌŽƵŶĚ  ? ?A? ŝŶ ŵŽŶŽĐǇƚĞƐ ĂŶĚ  ? ?A? ŝŶ
granulocytes, but being virtually absent in lymphocytes 51.  
 
This disease mechanism is not limited to NLRP3 but has also been reported with other genes 
associated with SAID. A 2015 study by Shinar et al ĚĞƐĐƌŝďĞĚ ƚŚĞ ĨŝƌƐƚ ƌĞƉŽƌƚĞĚ ĐĂƐĞ ŽĨ  ‘ĂĐƋƵŝƌĞĚ ?
FMF, as opposed to the conventionally defined autosomal recessive hereditary disorder, in a patient 
with post polycythaemia myelofibrosis due to the rare, pathogenic variant c.1955G>A, p.Arg652His 
in exon 10, affecting the PRYSPRY domain of pyrin, which is known to interact with IL- ?ɴ ĂŶĚ
caspase-1 55. However, the presence of this variant was restricted to myeloid cells, initially at 
negligible levels before the onset of fever, but rising to 46% of the total MEFV alleles after the 
disease onset. It was presumed that this variant became co-segregated with JAK2 mutations, leading 
to a proliferating clone. On the other hand this case study demonstrated the presence of the 
suggested heterozygous, low penetrance variant c.2113C>A, p.Gln705Lys 56, which is likely to have 
served as a modifying gene in myeloid cells, thereby upregulating the proinflammatory effects of 
mutated MEFV. It should be noted that this patient did not experience an inflammatory phenotype 
prior to FMF development, and, therefore, this clinically silent variant is unlikely to be always 
pathogenic, despite reports to the contrary 57. In line with these findings, clinical characterisation of 
47 FMF mutation negative patients (i.e. no detectable mutation using PCR for common mutations in 
MEFV), compared with those heterozygous for the disease, saw that the mutation-negative patients 
were less likely to experience joint attacks 58. As the reported phenotypes were only marginally 
distinctive, a number of conclusions could be derived; for example, there could be epigenetic 
modifications of the MEFV gene product, which could suggest the involvement of other, unknown 
genes. Alternatively, the occurrence of somatic mosaicism may explain these findings in that there 
may be (are) mutations in MEFV, but only in a very small subset cells that have not been identified 
and sequenced.  
The first case of somatic mosaicism in TRAPS was reported only recently in 2016 59. A 41-
year-old patient exhibiting a wide spectrum of symptoms as seen with SAIDs underwent analysis of 4 
genes NLRP3, MEFV, MVK and TNFRSF1A, where a 24 nucleotide deletion of the TNFRSF1A gene 
(c.255_278del) was detected in exon 3. Such deletions are associated with protein misfolding, which 
is likely to affect TNF binding. Although PCR and Sanger sequencing validated the presence of the 
mutated nucleotide peaks, the chromatogram peaks were evidently smaller than the wild-type. 
Targeted sequencing confirmed the presence of mosaicism, with a 7.6% mutant allele frequency in 
whole blood, and parental DNA corroborated with the wildtype sequence of TNFRSF1A, confirming 
the presence of somatic deletion in the patient.   
The initial account of somatic mosaicism in Blau Syndrome (BS) was first reported by de 
Inocencio et al. in 2015 60. Targeted deep sequencing of both haematological and non-
haematological derived DNA ascertained the presence of the p.Arg334Gln NOD2 mutation, first 
ƐƵƐƉĞĐƚĞĚĚƵƌŝŶŐ^ĂŶŐĞƌĐŚƌŽŵĂƚŽŐƌĂŵĂŶĂůǇƐŝƐŽĨĂ ‘ƐƵďƚůĞ ?ĂĚĞŶŝŶĞƉĞĂŬĂƚ ? ? ? ? ?ĂƐĐŽŵƉĂƌĞĚƚŽ
a decrease in the wild type. The mutated allelic frequency (MAF) lay  between 4.9%-11%, depending 
on the tissue of origin (monocytes showing the highest MAF), with parental screening showing an 
absence of this variant, thereby confirming its de-novo status. However more recently, the report of 
 ‘ŐŽŶŽƐŽŵĂů ŵŽƐĂŝĐŝƐŵ ?  ? somatic mutations affecting both body and gonadal tissue 61  ? where 3 
members of the family across 2 consecutive generations are affected with BS, has brought new 
information to light 62. Analysis of the same NOD2 variant (p.Arg334Gln) showed presence in the 
ĞŵďƌǇŽŶŝĐ ůĂǇĞƌƐ ĂŶĚ ƐŽŵĂƚŝĐ ĐĞůůƐ ? ƚŚĞ ĨŽƌŵĞƌ ƐƵŐŐĞƐƚŝǀĞ ŽĨ ƚŚĞ  ‘ŝŶƚƌĂĨĂŵŝůŝĂů ƌĞĐƵƌƌĞŶĐĞ ? ĂƐ ƚŚĞ
ƉĂƚŝĞŶƚ ?Ɛ ĚĂƵŐŚƚĞƌ ŝƐ ĂůƐŽ ĂĨĨĞĐƚĞĚ ? ĂŶĚ ĂůƐŽ ƚŚĂƚ ƐŽŵĂƚŝĐ ŵƵƚĂtion transmission is very rare and 
unlikely to occur. The determination of the degree of gonadal mosaicism would not only indicate the 
level of variant distribution in the body, but could also establish transmission risk to offspring, unlike 
germline mutations where there is a 50% chance of transmitting the mutated allele; although this 
study was unable to derive this figure. The conclusion that there are milder phenotypes on the BS 
spectrum associated with de novo mutations than those phenotypes seen in BS patients with 
germline mutations is a concept that has also been seen in other SAID, such as CAPS 54 63 and TRAPS 
59, as well as one BS case itself 60. With this particular case, the presence of a somatic NOD2 mutation 
ŝŶ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ŚĂĞŵĂƚŽƉŽŝĞƚŝĐ ĐĞůůƐ ŝƐ ůŝŬĞůǇ ƚŽ ďĞ ƚŚĞ ĐĂƵƐĞ ŽĨ ƚŚĞ ŵĂŝŶ ƐǇŵƉƚŽŵƐ ŽĨ ĂŶ
ŝŶĨůĂŵŵĂƚŽƌǇ ŶĂƚƵƌĞ ? ,ŽǁĞǀĞƌ ? ƚŚĞ ůĂƚĞƌ ĚŝƐĞĂƐĞ ŽŶƐĞƚ ĂŶĚĂ  ‘ƌĞůĂƚŝǀĞůǇ ďĞŶŝŐŶ ĐŽƵƌƐĞ ? ? ǁŝƚŚ
decreased joint involvement, in the 2015 study 60, as compared to other germline cases is indicative 
of a wider range of clinical phenotypes, albeit very dependent on the level of mosaicism. 
 Recognition and diagnosis of patients with somatic mutations in everyday clinical practice 
remains a challenge. Patients will present with variable expression of signs and symptoms and 
identification of somatic mutation is a technically highly demanding and expensive process. One 
option to help with selection of patients, in whom further investigation for somatic mutations is 
warranted, is to use response to therapy as part selection process. For example IL-1 blockade is a 
very effective treatment for a number of monogenic SAID with underlying dysregulation of IL-1 
release, such as CAPS, FMF and TRAPS 10. In these disorders administration of anti-IL1 therapies 
leads to rapid resolution of symptoms and disease control. We have recently used a trial of anakinra, 
which is a short acting IL-1 receptor antagonist, to identify patients presenting with SAID of unknown 
etiology 42.  These were adult patients presenting with features suggestive of SAID, but who did not 
have any known germline mutations in a number of SAID-associated genes, and who did not meet 
ƚŚĞ ĚŝĂŐŶŽƐƚŝĐ ĐƌŝƚĞƌŝĂ ĨŽƌ ƉŽůǇŐĞŶŝĐ ^/ ? ƐƵĐŚ ĂƐ ^ƚŝůů ?Ɛ ĚŝƐĞĂƐĞ ? /Ŷ  ? ŽƵƚ ŽĨ  ? ? ƉĂƚŝĞŶƚƐ ?
administration of anakinra resulted in full symptom control within 4-6 weeks of starting treatment, 
and this was associated with a clinically significant reduction in C-reactive protein (CRP) levels. Such 
rapid and profound responses to a very targeted therapy implies that dysregulation of the IL-1 
pathway is important in the pathogenesis of the disease in question.  Therefore, it highly probable 
that some of these cases may turn out to have a somatic mutation in one of the relevant SAID genes.  
Conclusions 
It was not possible within the scope of this review to mention all interesting disorders of an 
autoinflammatory nature discovered in the last 12-18 months. However we have tried to provide an 
overview of those selected conditions and concepts which we believe are important to define this 
rapidly evolving field. We have briefly mentioned some of the more established therapies, such as 
biologicals directed against IL-1; however small molecular inhibitors targeting JAK kinases, or the 
recently discovered MCC950 which inhibits the NLRP3 inflammasome 64 are being introduced into 
clinical practice and may change the way we treat autoinflammatory disorders in the future. 
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Figure 1. The Expanded Immunological Disease Continuum-including primary immunodeficiencies 
with autoinflammatory and/or autoimmune features  
FMF  ? Familial Mediterranean Fever; TRAPS - TNF receptor associated periodic syndrome; CAPS- 
cryopyrin-associated periodic fever syndromes; HIDS- hyperimmunoglobulinaemia D with periodic 
fever syndrome; PAPA Pyogenic Arthritis, Pyoderma gangrenosum and Acne; DIRA-Deficiency of IL-1 
Receptor antagonist; PAAND pyrin-associated autoinflammation with neutrophilic dermatosis; 
PRAAS-proteasome-associated autoinflammatory syndrome; AOSD-ĚƵůƚKŶƐĞƚ^ƚŝůů ?ƐĚŝƐĞĂƐĞ ? BD- 
ĞŚĕĞƚ ?ƐĚŝƐĞĂƐĞ;  sJIA- systemic juvenile idiopathic arthritis; ALPS-Autoimmune lymphoproliferative 
syndrome; APS-1 Autoimmune polyendocrine syndrome type 1 of APECED- autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy; IPEX Immunodysregulation 
polyendocrinopathy enteropathy X- linked syndrome 
 
